Q BioMed Inc. (QBIO)
| Market Cap | 24.58M |
| Revenue (ttm) | 30,000 |
| Net Income (ttm) | -13.25M |
| Shares Out | 22.43M |
| EPS (ttm) | -0.65 |
| PE Ratio | n/a |
| Forward PE | 98.04 |
| Dividend | n/a |
| Dividend Yield | n/a |
| Trading Day | February 26 |
| Last Price | $1.05 |
| Previous Close | $1.09 |
| Change ($) | -0.04 |
| Change (%) | -3.67% |
| Day's Open | 1.10 |
| Day's Range | 1.01 - 1.10 |
| Day's Volume | 57,063 |
| 52-Week Range | 0.9001 - 3 |
NEW YORK, Feb. 1, 2021 /PRNewswire/ -- Q BioMed Inc. (OTCQB: QBIO), a commercial stage biotech company, announced today that it has been awarded a contract with UroGPO, the largest Group Purch...
NEW YORK, Jan. 27, 2021 /PRNewswire/ -- Q BioMed Inc. (OTCQB: QBIO), announced today that the U.S. Food and Drug Administration's Office of Orphan Products Development has granted Orphan Drug ...
NEW YORK, Dec. 29, 2020 /PRNewswire/ -- Q BioMed Inc. (OTCQB: QBIO), a commercial stage biotech company, today issued a letter to shareholders. Dear Fellow Shareholders, As 2020 draws to a clo...
NEW YORK, Dec. 21, 2020 /PRNewswire/ -- Q BioMed, Inc. (OTCQB: QBIO) is pleased to announce that its technology partner Mannin Research Inc. (MRI), a private Canadian biotechnology company, is...
About QBIO
Q BioMed, a biomedical acceleration and development company, focuses on licensing, acquiring, and providing resources to life sciences and healthcare companies. The company offers Strontium Chloride SR89, a radiopharmaceutical therapeutic for the treatment of bone cancer pain therapies; and Metastron, a radiopharmaceutical drug for metastatic cancer bone pain therapy. It is also developing Man-01, a pre-clinical lead candidate for the treatment of primary open angle glaucoma; QBM-001 for rare pediatric non-verbal autism spectrum disorder; and U... [Read more...]
| Industry Biotechnology | Founded 2013 |
| CEO Denis D. Corin | Employees 1 |
| Stock Exchange OTCMKTS | Ticker Symbol QBIO |